Shilpa Medicare Limited Launches Lenvatinib Capsules (12mg, 18 mg and 24 mg) in India under the brand name Lenshil®

Shilpa Medicare Limited has received approval from CDSCO, New Delhi for manufacturing and sale of Lenvatinib Capsules, 12, 18 and 24 mg in India. Shilpa will commercialize the product under the brand name Lenshil®. Lenshil® 12 mg and Lenshil® 18 mg will be launched immediately followed by Lenshil® 24 mg.

Shilpa Medicare Limited is the first company to receive approval for Lenvatinib Capsules, 12, 18 and 24 mg in India. The company is already marketing the 4 mg and 10 mg strengths. The first time launch of this new drug in India will offer great benefits in terms of flexibility of dosage and patient convenience in specific cancer indications. For treating hepatocellular carcinoma, the recommended dosage is 12 mg orally once daily for patients greater than or equal to 60 kg. For treating Renal Cell Carcinoma (RCC) the recommended dosage is 18 mg orally once daily and for Differentiated Thyroid Cancer the recommended daily dose of Lenvatinib is 24 mg once daily.

Shilpa's first-in-India - Lenshil® 12 mg, Lenshil® 18 mg and Lenshil® 24 mg will allow physicians and patients to administer only one capsule instead of three capsules of the currently available 4 mg and 10 mg strengths. Lenshil® is a bioequivalent and pharmaceutically equivalent version of the brand product Lenvima® of Eisai, USA.

Shilpa Medicare Limited, is a research driven, global, integrated pharmaceutical company, headquartered in Raichur, Karnataka, India and is engaged in research and development, manufacturing and sale of oncology drugs and formulations.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 247.10 as compared to the previous close of Rs. 253.95. The total number of shares traded during the day was 14327 in over 604 trades.

The stock hit an intraday high of Rs. 256.85 and intraday low of 246.40. The net turnover during the day was Rs. 3590148.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 CDSCO Approval LenvatinibCapsules India Manufacturing Sale